General
Preferred name
IDEBENONE
Synonyms
Idebenonum ()
CV-2619 ()
Avan ()
IDEBENONE58186-27-9 ()
Oristar hdu ()
Raxone ()
NSC-759228 ()
Hydroxydecyl ubiquinone ()
Idebenona ()
Sovrima ()
P&D ID
PD000297
CAS
58186-27-9
Tags
available
drug
Approved by
EMA
First approval
2015
Drug indication
MELAS
Friedreich's ataxia
Cognitive impairment
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 ¦ÌM)[1]. Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells[2]. Idebenone quickly crosses the blood-brain barrier.
PRICE 33
DESCRIPTION Idebenone is a synthetic analogue of ubiquinone, a vital cell antioxidant and essential component of the Electron Transport Chain. Idebenone is indicated for use by the European Medicines Agency for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy. (Enamine Bioactive Compounds)
DESCRIPTION Idebenone (CV-2619) is a synthetic analogue of ubiquinone (Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC). (TargetMol Bioactive Compound Library)
DESCRIPTION Antioxidant (Tocris Bioactive Compound Library)
Cell lines
4
Organisms
1
Compound Sets
29
AdooQ Bioactive Compound Library
A11707
Cayman Chemical Bioactives
15475
ChEMBL Approved Drugs
CHEMBL252556
ChEMBL Drugs
CHEMBL252556
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB09081
DrugBank Approved Drugs
DB09081
DrugCentral
1416
DrugCentral Approved Drugs
1416
DrugMAP
DMQFDRC
DrugMAP Approved Drugs
DMQFDRC
DrugMatrix
Enamine Bioactive Compounds
EBC-15034
Enamine BioReference Compounds
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL252556
MedChem Express Bioactive Compound Library
HY-N0303
Natural product-based probes and drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
idebenone
TargetMol Bioactive Compound Library
T0412
The Spectrum Collection
Tocris Bioactive Compound Library
3002
Withdrawn 2.0
EMA20
ZINC Tool Compounds
ZINC000001542890
External IDs
33
Properties
(calculated by RDKit )
Molecular Weight
338.21
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
12
Ring Count
1
Aromatic Ring Count
0
cLogP
3.46
TPSA
72.83
Fraction CSP3
0.68
Chiral centers
0.0
Largest ring
6.0
QED
0.44
Structural alerts
1
quinone_A(370)
[!#6&!#1]=[#6]1[#6]=,:[#6][#6](=[!#6&!#1])[#6]=,:[#6]1
PAINS Family A
Custom attributes
(extracted from source data)
Target
antioxidant
Apoptosis
Mitochondrial Metabolism
Ferroptosis
ROS
Primary Target
Antioxidants
Member status
virtual
MOA
"Calcium Channel Modulators
Antioxidants"
Calcium Channel Modulators
calcium channel modulator
Disease Area
neurology/psychiatry, ophthalmology
Indication
Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)
ATC
N06BX13
Biosynthetic Origin
Terpenoid, Other (Shikimate)
Therapeutic Indication
Nootropic
Therapeutic Class
CNS & PNS
Pathway
Metabolism
oxidation-reduction
Metabolic Enzyme/Protease
Source data